

## Trametinib, MEK inhibitor

| Catalog      | Unit  |
|--------------|-------|
| TBI4759-10MG | 10 mg |
| TBI4759-50MG | 50 mg |

### Product Details

**Formal Name:** N-{3-[3-Cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide

**Alternate Names:** GSK1120212; JTP-74057

**Molecular Formula:** C<sub>26</sub>H<sub>23</sub>FIN<sub>5</sub>O<sub>4</sub>

**Formula Weight:** 615.40

**CAS Number:** 871700-17-3


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 20 mg/ml with warming)

**Storage:** -20°C

**Stability:** ≥ 1 year.



### Applications

MEK inhibitor

### Functions

Trametinib is a highly potent (IC<sub>50</sub> uMEK1 = 0.7 nM, pp-MEK1 = 14.9 nM) and selective MEK inhibitor displaying selective inhibition of proliferation in various BRAF mutant cancer cell lines (IC<sub>50</sub> ACHN = 9.8 nM; IC<sub>50</sub> HT-29 = 0.57 nM). It is approved for use against unresectable or metastatic BRAF-mutant melanoma alone or in combination with Dabrafenib. Trametinib can limit outgrowth of tumors without directly inhibiting tumor cell proliferation via abrogation of cytokine-driven expansion of monocytic myeloid-derived suppressor cells (mMDSC) through a mechanism involving CD8<sup>+</sup> T cells. Trametinib also displays potent anti-arthritis effects.

### Application Procedures

First dissolved in DMSO (up to 20 mg/ml with warming), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 2 months.

**For research use only.**